Inflammasome Activation in Human Macrophages Induced by a LDL (-) Mimetic Peptide

Inflammation. 2020 Apr;43(2):722-730. doi: 10.1007/s10753-019-01159-y.

Abstract

The inflammasome is responsible for maturation of interleukin-1β (IL-1β) and interleukin-18 (IL-18) contributing to the inflammatory process in atherosclerosis. It is shown here that an electronegative low-density lipoprotein [LDL (-)] apoB-100 mimetic peptide can activate the transcriptional and posttranslational signs needed for complete inflammasome activation. This peptide, named p2C7, can activate the Toll-like receptor 4 (TLR4) that induces NF-κB activation and the transcription of inflammasome components. After blocking TLR4 with a neutralizing antibody, inflammasome component (NLRP3, CASP1, and ASC) and IL1b and IL18 gene downregulation occurred in human-derived macrophages stimulated with p2C7 or LDL (-). Moreover, the posttranslational signal was activated by the interaction between p2C7 and the lectin-type oxidized LDL receptor 1 (LOX-1), as demonstrated by the induction of caspase-1 cleavage in macrophages. The blockage of either TLR4 or LOX-1 decreased IL-1β and IL-18 secretion by human-derived macrophages as both pathways are necessary for complete inflammasome activation. These findings suggest a mechanism by which macrophages transduce the pro-inflammatory signal provided by LDL (-) ApoB-100 and its mimetic peptides to activate the inflammasome protein complex what may be relevant for the inflammatory process in atherosclerosis.

Keywords: LDL (−); atherosclerosis; inflammasome; mimotope; peptide.

MeSH terms

  • Apolipoprotein B-100 / pharmacology*
  • Biomimetic Materials / pharmacology*
  • Cells, Cultured
  • Humans
  • Inflammasomes / metabolism*
  • Lipoproteins, LDL / pharmacology*
  • Macrophages / drug effects
  • Macrophages / metabolism*
  • Monocytes / drug effects
  • Monocytes / metabolism

Substances

  • Apolipoprotein B-100
  • Inflammasomes
  • Lipoproteins, LDL